期刊文献+

Active surveillance monitoring: the role of nove biomarkers and imaging

Active surveillance monitoring: the role of nove biomarkers and imaging
原文传递
导出
摘要 "CANCER" is a disease state that leads to progressive illness that is uniformly fatal without treatment. Hippocrates invoked the Greek word karkinos, or "crab" to describe tumors he observed. For centuries, "CANCER" remained a disease that was recognized primarily in its locally advanced or metastatic stage, when it was almost uniformly fatal. "CANCER" is a disease state that leads to progressive illness that is uniformly fatal without treatment. Hippocrates invoked the Greek word karkinos, or "crab" to describe tumors he observed. For centuries, "CANCER" remained a disease that was recognized primarily in its locally advanced or metastatic stage, when it was almost uniformly fatal.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2015年第6期882-884,I0006,共4页 亚洲男性学杂志(英文版)
  • 相关文献

参考文献18

  • 1El Hajj A, Ploussard G, de la Taille A, AIIory Y, Vordos D, et al. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int2013; 111:53 9.
  • 2Tosoian J J, Trock B J, Landis P, Feng Z, Epstein JI, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Onco12011., 29: 2185-90.
  • 3Fall K, Garmo H, Andr~n O, BilI-Axelson A, Adolfsson J, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 526-32.
  • 4Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28:2810 6.
  • 5Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289:2695 700.
  • 6van As N J, Norman AR, Thomas K, Khoo VS, Thompson A, et al. Predicting the probability of deferred radical treatment for Iocalised prostate cancer managed by active surveillance. Eur Uro! 2008; 54: 1297-305.
  • 7Tosoian J J, Loeb S, Feng Z, Isharwal S, Landis P, etal. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. JUrot 2012; 188: 1131-6.
  • 8Tosoian J J, Loeb S, Kettermann A, Landis P, Elliot D J, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Uro12010; 183: 534-8.
  • 9Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, etal. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013; 19: 2442-50.
  • 10Berg KD, Vainer B, Thomsen FB, Roder MA, Gerds TA,eta/. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Uro! 2014; 66.. 851 60.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部